Notably, this is the first reported case of LCH harboring an IDH2 mutation, raising the potential therapeutic utility of a Food and Drug Administration‐approved IDH2 inhibitor in this entity. The gene discussed is IDH2; the disease is Langerhans cell histiocytosis.